illumina

Unlock scalable oncology workflows with NextSeq™ 2000 System

Bring flexibility and efficiency to your oncology research from sample to report—all from one benchtop sequencing system. The NextSeq 2000 System enables you to scale from targeted panels to comprehensive genomic profiling (CGP). Now you and your staff can confidently pivot to wherever your oncology needs take you.

Targeted panels

Targeted testing includes a subset of well-characterized cancer-related biomarkers, enabling fast and affordable genomic profiling within a sample. These can also be a stepping stone for labs expanding into comprehensive testing.

Large panels

Large pan-cancer panels analyze hundreds of genes in a single test, covering major variant classes and genomic signatures. They help identify key mutations, reduce the need for sequential testing, and maximize insights for complex cases.



Designed for ease and dependability

ENHANCED ACCESSIBILITY

Onboard next-generation sequencing (NGS) easily in house with prevalidated workflows across flexible batch sizes for both targeted panels and CGP.

ROBUST TECHNOLOGY

Have confidence in your workflows while using a globally adopted, rigorously validated, and widely cited oncology research offering.

ONE VENDOR

Access support from one team of experts across your entire workflow, from sample preparation to reporting.

Access targeted testing with Pillar® oncoReveal™ panels

Reveal key mutations across multiple cancer types with efficient single-tube enrichment. With oncoReveal panels:

- Achieve accurate sample amplification, even with limited sample input or poor-quality samples
- Receive results across multiple cancer types
- Access a rapid and flexible workflow

Panel	Sample type	No. of samples	Total workflow time
oncoReveal Core LBx Panel	cfDNA from plasma	up to 48	< 2 days
oncoReveal Essential LBx Panel	cfDNA from plasma	up to 48	< 2 days
oncoReveal Fusion LBx Panel	cfRNA from plasma	Does not contribute significantly to multiplex capacity	< 2 days

Cell-free DNA (cfDNA)

Enable genomic profiling with TruSight™ Oncology 500

Access next-generation large panel genomic profiling with precise oncology research applications. With TruSight Oncology 500:

- Obtain reliable results with robust hybrid–capture chemistry
- Use an assay with comprehensive pan-cancer content designed with the future in mind
- Get validated performance specifications for all variant classes and gene signatures (TMB, MSI, HRD*)
- Choose from manual or automated library prep (384 Unique Dual Indexes)
- Process flexible batch sizes with third-party automation methods

Sample type	No. of samples	Total workflow time
Liquid biopsy (blood)	4	3 days
Tissue (FFPE)	8–36	3–4 days

Tumor mutational burden (TMB)

Microsatellite instability (MSI)

Homologous recombination deficiency (HRD)

*HRD available with TruSight Oncology 500 v2 tissue only.

Streamlined workflows

LIBRARY PREP	SEQUENCING	SECONDARY ANALYSIS	INSIGHTS & REPORTING
TruSight Oncology 500 v2 (FFPE)	NextSeq 1000 and NextSeq 2000 Systems	DRAGEN™ TruSight Oncology 500 (on-premises and cloud)	Illumina Connected Insights Other options, such as Velsera Clinical Genomics Workspace, are also available
TruSight Oncology 500 ctDNA v2 (blood)		DRAGEN TruSight Oncology 500 ctDNA (on-premises and cloud)	

Leverage consistent technology and panel design, from targeted to large panels with Illumina.

illumina®

Start transforming your oncology research.

illumina.com/NextSeq-Expertise